ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
FAM3A Inhibits Plasma Triglyceride Levels via Microvasculature-Involved Enhancement of VLDL-Triglyceride Hydrolysis and Lipid Uptake.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
FAM3 metabolism regulating signaling molecule A (FAM3A) is ubiquitously expressed. However, its biological role remains largely unknown. This study investigated the regulatory roles of FAM3A in plasma triglyceride (TG) levels. Proteomics revealed upregulated lipid metabolism-related proteins, including CD36 and TCF15, in skeletal muscle of FAM3A-transgenic mice. Clinically, plasma FAM3A was reduced in patients with metabolic disorders. FAM3A-transgenic mice and recombinant FAM3A (rcFAM3A) injection in mice significantly reduced plasma TG levels, upregulated tissue lipid uptake and lipid transporter expression in skeletal muscle. Microvascular endothelial cells (MVECs) from soleus and heart of FAM3A-transgenic mice or rcFAM3A-infused mice exhibited increased fatty acid (FA) uptake and trans-endothelial transport. Accordingly, FAM3A increased CD36 and TCF15 expression in MVECs derived from soleus, and increased CD36 expression was also observed in both C2C12 and MVECs treated by FAM3A in vitro. The siRNA-mediated knockdown of TCF15 or CD36 effectively inhibited FA uptake. Notably, FAM3A increased the luminal localization and activity of lipoprotein lipase (LPL) in endothelium, enhancing plasma VLDL-TG hydrolysis both in vivo and in vitro. However, FAM3A showed no effect on hepatic VLDL production or intestinal lipid absorption. Importantly, FAM3A exerted these effects primarily by activating PPARα signaling, as pharmacological blockage of PPARα with GW6471 inhibited FAM3A-induced upregulation of CD36 and TCF15 expression, endothelial lumen LPL localization and activity, FA uptake and trans-endothelial transport, and plasma TG clearance. Collectively, these findings reveal a pivotal role of FAM3A in plasma TG catabolism, identifying that the FAM3A/PPARα axis drives LPL-mediated TG lipolysis, lipid-transendothelial delivery, and tissue FA uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.